These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 25096495)

  • 1. Short communication: focal encephalitis related to viral escape and resistance emergence in cerebrospinal fluid in a patient on lopinavir/ritonavir monotherapy with plasma HIV-1 RNA suppression.
    Imaz A; Cayuela N; Niubó J; Tiraboschi JM; Izquierdo C; Cabellos C; Podzamczer D
    AIDS Res Hum Retroviruses; 2014 Oct; 30(10):984-7. PubMed ID: 25096495
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of protease inhibitor monotherapy vs. triple therapy: meta-analysis of data from 2303 patients in 13 randomized trials.
    Arribas JR; Girard PM; Paton N; Winston A; Marcelin AG; Elbirt D; Hill A; Hadacek MB
    HIV Med; 2016 May; 17(5):358-67. PubMed ID: 26709605
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ongoing HIV replication in cerebrospinal fluid under successful monotherapy.
    Bierhoff M; Boucher CA; Fibriani A; Ten Kate RW
    Antivir Ther; 2013; 18(4):641-3. PubMed ID: 23344463
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Late treatment failures in cerebrospinal fluid in patients on long-term maintenance ART with ritonavir-boosted protease PI monotherapy.
    Kahlert C; Bregenzer A; Gutmann C; Otterbech S; Hoffmann M; Schmid P; Vernazza P
    Infection; 2016 Jun; 44(3):329-35. PubMed ID: 26661659
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effectiveness of ritonavir-boosted protease inhibitor monotherapy in the clinical setting: same results as in clinical trials? The PIMOCS Study Group.
    Curran A; Monteiro P; Domingo P; Villar J; Imaz A; Martínez E; Fernández I; Knobel H; Podzamczer D; Iribarren JA; Peñaranda M; Crespo M;
    J Antimicrob Chemother; 2014 May; 69(5):1390-6. PubMed ID: 24415645
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Marked increase of the astrocytic marker S100B in the cerebrospinal fluid of HIV-infected patients on LPV/r-monotherapy.
    Du Pasquier RA; Jilek S; Kalubi M; Yerly S; Fux CA; Gutmann C; Cusini A; Günthard HF; Cavassini M; Vernazza PL;
    AIDS; 2013 Jan; 27(2):203-10. PubMed ID: 23032410
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term (96-week) follow-up of antiretroviral-naïve HIV-infected patients treated with first-line lopinavir/ritonavir monotherapy in the MONARK trial.
    Ghosn J; Flandre P; Cohen-Codar I; Girard PM; Chaix ML; Raffi F; Dellamonica P; Ngovan P; Norton M; Delfraissy JF;
    HIV Med; 2010 Feb; 11(2):137-42. PubMed ID: 19682100
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HIV monotherapy with ritonavir-boosted protease inhibitors: a systematic review.
    Bierman WF; van Agtmael MA; Nijhuis M; Danner SA; Boucher CA
    AIDS; 2009 Jan; 23(3):279-91. PubMed ID: 19114854
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Protease inhibitor monotherapy.
    Pérez-Valero I; Arribas JR
    Curr Opin Infect Dis; 2011 Feb; 24(1):7-11. PubMed ID: 21150592
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lopinavir-ritonavir monotherapy versus lopinavir-ritonavir and two nucleosides for maintenance therapy of HIV.
    Pulido F; Arribas JR; Delgado R; Cabrero E; González-García J; Pérez-Elias MJ; Arranz A; Portilla J; Pasquau J; Iribarren JA; Rubio R; Norton M;
    AIDS; 2008 Jan; 22(2):F1-9. PubMed ID: 18097218
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Boosted protease inhibitor monotherapy. What have we learnt after seven years of research?
    Pulido F; Matarranz M; Rodríguez-Rivera V; Fiorante S; Hernando A
    AIDS Rev; 2010; 12(3):127-34. PubMed ID: 20842201
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cerebrospinal fluid and plasma HIV-1 RNA levels and lopinavir concentrations following lopinavir/ritonavir regimen.
    Yilmaz A; Ståhle L; Hagberg L; Svennerholm B; Fuchs D; Gisslén M
    Scand J Infect Dis; 2004; 36(11-12):823-8. PubMed ID: 15764168
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dual therapy with lopinavir and ritonavir plus lamivudine versus triple therapy with lopinavir and ritonavir plus two nucleoside reverse transcriptase inhibitors in antiretroviral-therapy-naive adults with HIV-1 infection: 48 week results of the randomised, open label, non-inferiority GARDEL trial.
    Cahn P; Andrade-Villanueva J; Arribas JR; Gatell JM; Lama JR; Norton M; Patterson P; Sierra Madero J; Sued O; Figueroa MI; Rolon MJ;
    Lancet Infect Dis; 2014 Jul; 14(7):572-80. PubMed ID: 24783988
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Switching to lopinavir/ritonavir with or without abacavir/lamivudine in lipoatrophic patients treated with zidovudine/abacavir/lamivudine.
    Bernardino JI; Pulido F; Martinez E; Arrizabalaga J; Domingo P; Portilla J; Ocampo A; Muñoz J; Torres R; Arribas JR;
    J Antimicrob Chemother; 2013 Jun; 68(6):1373-81. PubMed ID: 23386261
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ritonavir-boosted lopinavir as maintenance monotherapy in HIV-infected patients who achieved viral suppression during a second-line protease inhibitor-based regimen: a pilot randomized trial (BIDI-MONO).
    Siripassorn K; Chottanapund S; Prasithsirikul W; Manosuthi W
    J Int Assoc Provid AIDS Care; 2014; 13(4):353-60. PubMed ID: 25513033
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ritonavir-boosted protease inhibitor monotherapy for the treatment of HIV-1 infection.
    Sahali S; Chaix ML; Delfraissy JF; Ghosn J
    AIDS Rev; 2008; 10(1):4-14. PubMed ID: 18385776
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lopinavir/ritonavir monotherapy as a simplification strategy in routine clinical practice.
    Moltó J; Santos JR; Negredo E; Miranda C; Videla S; Clotet B
    J Antimicrob Chemother; 2007 Aug; 60(2):436-9. PubMed ID: 17556354
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Virological efficacy in cerebrospinal fluid and neurocognitive status in patients with long-term monotherapy based on lopinavir/ritonavir: an exploratory study.
    Santos JR; Muñoz-Moreno JA; Moltó J; Prats A; Curran A; Domingo P; Llibre JM; McClernon DR; Bravo I; Canet J; Watson V; Back D; Clotet B
    PLoS One; 2013; 8(7):e70201. PubMed ID: 23922957
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Lopinavir/ritonavir in new simplification strategies in antiretroviral therapy].
    Sebastián Mde L; Pardo OB; Ortega FP
    Enferm Infecc Microbiol Clin; 2014 Nov; 32 Suppl 3():12-7. PubMed ID: 25542870
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lopinavir/ritonavir monotherapy or plus zidovudine and lamivudine in antiretroviral-naive HIV-infected patients.
    Delfraissy JF; Flandre P; Delaugerre C; Ghosn J; Horban A; Girard PM; Norton M; Rouzioux C; Taburet AM; Cohen-Codar I; Van PN; Chauvin JP
    AIDS; 2008 Jan; 22(3):385-93. PubMed ID: 18195565
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.